Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cartesian Therapeutics (RNAC) Preferred Dividend Payments (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Preferred Dividend Payments for 4 consecutive years, with $2.6 million as the latest value for Q2 2025.

  • On a quarterly basis, Preferred Dividend Payments fell 37.55% to $2.6 million in Q2 2025 year-over-year; TTM through Jun 2025 was $6.8 million, a 62.45% increase, with the full-year FY2016 number at $4.6 million, down 37.75% from a year prior.
  • Preferred Dividend Payments was $2.6 million for Q2 2025 at Cartesian Therapeutics, down from $4.2 million in the prior quarter.
  • In the past five years, Preferred Dividend Payments ranged from a high of $4.2 million in Q2 2024 to a low of $2.6 million in Q2 2025.